Avedro, Inc.

230 Third Avenue

Waltham, MA  02451

Tel: 781.768.3400


Leadership:
David Muller, Ph.D.
President & CEO


Website:
www.avedro.com

Avedro, Inc.

Flagship Partners:  David Berry
Initial Investment: 
2009
Status: 
Private

Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross‐linking and refractive correction. Avedro's products include capital equipment and related single dose pharmaceuticals. The KXL® System's cross‐linking, in combination with its pharmaceuticals, is used to treat keratoconus and corneal ectasia outside the United States. Those products are also used in a procedure known as Lasik Xtra®. Over 75,000 surgeries have been successfully performed outside the US using Avedro's KXL System. Avedro distributes its products in 62 countries through 33 ophthalmic distributors with 115 sales and service representatives. Avedro products that have received CE Mark include: the KXL System for performing Lasik Xtra and Accelerated Cross‐Linking, the KXL II™ System for performing PiXL™, and the Avedro family of proprietary single dose pharmaceutical formulations. Avedro's KXL System and single dose pharmaceutical products are currently being used in three Phase III US clinical trials involving over 100 US clinical sites. Avedro products are not for sale in the US.

David Berry is on the Board of Directors.